Latest Safety News

PYC Therapeutics has announced promising pre-clinical results for its RNA-based drug candidate PYC-002, targeting the genetic root of Phelan-McDermid Syndrome, with clinical trials expected to begin in 2026.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

GenusPlus Group has upgraded its FY2025 EBITDA guidance following strong quarterly results and acquisitions, while securing a significant $20 million rail infrastructure contract through its recent acquisition MGC Solutions.

Brightstar Resources has announced maiden Ore Reserves for its Second Fortune and Fish underground mines, underpinning FY26 production under a key Ore Purchase Agreement with Genesis Minerals. The company also signals significant exploration upside and an imminent Definitive Feasibility Study that could expand its footprint in the WA Goldfields.

Astron Corporation has received the Victorian Government's final regulatory green light for its Donald Rare Earths and Mineral Sands Project, paving the way for construction and financing. This milestone advances a strategically vital project aimed at supplying critical minerals for clean energy and defense.

Element 25 Limited advances its global manganese strategy with a $50 million loan for its Butcherbird Mine expansion and a $166 million US Department of Energy grant for a Louisiana battery-grade manganese refinery.

Tasmea Limited forecasts a robust 34% increase in net profit after tax for FY26, driven by a record order book and strategic acquisitions, while reaffirming its FY25 earnings guidance.

Li-S Energy has secured a collaboration and supply agreement with a leading defence technology firm to test its lithium-sulfur batteries for military applications, marking a strategic step into the global defence sector.

Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.

AIC Mines has secured $55 million through a well-supported placement to fund major expansions at its Eloise mine and the development of the Jericho copper project, backed by strategic investor Hawke’s Point.

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.